http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
3D프린팅 주형의 표면품질 향상을 위한 도형제 적용기술 연구
이환종,양정직,현효진 한국생산제조학회 2018 한국생산제조학회지 Vol.27 No.6
Three-dimensional (3D) printing technology is a new and widely use technology in the manufacturing industry. However, the domestic manufacturing industry is underutilized due to various manufacturing flaws and surface quality problems. This study intended to derive ways to improve the surface quality of products by improving the surface roughness of the sand mold manufactured by 3D printing. The test results confirmed improved viscosity control of the mold wash coated on the surface of the sand mold. In conclusion, it was possible to derive that the mold wash had a direct effect on the sand mold surface and to improve surface quality through coating methods on the mold and core.
이환종 대한화학요법학회 1992 대한화학요법학회지 Vol.10 No.1
감기(The common cold; nasopharyngitis ; URI) 감기는 비충혈(nasal, stuffiness), 재채기, 비루, 인두자극과 경한 발열을 특징으로 하는 급성 전염성 바이러스 질환이다. 상기도 감염증(upper respiratory infection)과 비인두염(nasopharyngitis)이 흔히 동의어로 쓰이나, 상기도 감염증은 좀더 포괄적인 단어이며, 대부분의 감기에서 인두염이 관찰 되지 않는다.
이환종,조대선,김윤경,이현주,김경효,이도경,Carlo Curina,Marco Costantini,Silvia Barbi,Yan Miao,Michele Pellegrini 대한백신학회 2019 Clinical and Experimental Vaccine Research Vol.8 No.2
Purpose: Results from a post-marketing study to generate evidence on 1-year antibody persistence and safety following vaccination of infants from South Korea with the quadrivalent meningococcal conjugate vaccine MenACWY-CRM. Materials and Methods: In this phase IV, open-label, multi-center study (NCT02446691), 128 infants received MenACWY-CRM at ages 2, 4, 6, and 12 months. One-year antibody persistence following the full vaccination course was evaluated (primary objective) for the four meningococcal serogroups (Men) by serum bactericidal activity assay using human or rabbit complement (hSBA/rSBA). Immune responses at 1-month post-vaccination and safety were also assessed. Results: The percentage of children with hSBA titers ≥8 ranged between 94% (MenA) and 100% (MenY/W) 1-month post-vaccination, and from 39% (MenA) to 89% (MenY) 1-year post-vaccination. At least 99% and 92% of children had rSBA titers ≥8 and ≥128 against each meningococcal serogroup, 1-month post-vaccination. One-year post-vaccination, the percentage of children with rSBA titers ≥8 and ≥128 ranged from 54% (MenC) to 99% (MenA) and from 30% (MenC) to 98% (MenA). Geometric mean titers declined from 1-month to 1-year post-vaccination, when they varied between 6.8 (MenA) and 53.6 (MenW) by hSBA and between 17.2 (MenC) and 2,269.5 (MenA) by rSBA. At least one solicited and unsolicited adverse event was reported for 79% and 66% of children. Of 36 serious adverse events reported, none were vaccination-related. Conclusion: Antibody persistence (hSBA/rSBA titers ≥8) was determined in 39%-99% of children 1 year after a 4-dose MenACWY-CRM series during infancy, with an acceptable clinical safety profile.
이환종,정혜림 대한화학요법학회 1987 대한화학요법학회지 Vol.5 No.2
지난 10여년간 의학의 발전과 함께 새로운 항생제가 쏟아져 나오고 있으며, 또 감염성 질환을 일으키는 균들도 주위 환경의 변화와 더불어, 특히 항생제의 남용과 함께, 항생제에 대한 감수성이 변하고 있다. 이러한 상황에서 각 세균에 의한 감염성 질환에 대해 적절한 항생제를 선택하기 위해서는, 질병을 일으키는 균 및 이에 대응하는 항생제의 변천에 대한 최신지견을 항상 접하고 있어야 하겠다. 한편 새로운 항생제들은 소아에 대한 임상시험은 제한된 것이 많아서, 소아에서의 약물역동, 효과, 부작용등의 충분한 검토가 이루어지지 않은 것이 대부분이며, 새로이 개발된 약제일수록 그 비용이 비싸므로, 특히 소아과 의사로서는, 새로운 항생제의 선택에 신중을 기해야 한다.
이환종 대한소아청소년과학회 2006 Clinical and Experimental Pediatrics (CEP) Vol.49 No.3
Streptococus pneumoniae is an important cause of invasive infections as well as non-invasive infections such as acute otitis media and sinusitis both in children and adults. Resistance of S. pneumoniae to multiple antimicrobials is increasing and poses therapeutic challenges, and prevention became more important. 23-valent polysaccharide vaccine has been used for the last several decades, but is not effective in children <2 years of age, the highest risk group of invasive diseases. Recently, a 7- valent pneumococcal protein conjugate vaccine(PCV) which is effective in infants and young children has been developed. The efficacy of PCVs against invasive pneumococcal disease and pneumonia is well established and is documented in several well-conducted studies. However, the effect of PCVs on otitis media is less obvious and more complex. PCVs clearly reduce diseases caused by vaccine- type(VT) pneumococci, but replacement of VT serotypes by non-VT serotypes in nasopharyngeal carriage of S. pneumoniae is responsible for the increase in acute otitis media caused by non-VT serotypes. Three years after introduction of PCV in the US, some increase of invasive infections with serotype 19A possibly due to serotype switching within certain vaccine type strains has been noted. Since most antibiotic-resistance in S. pneumoniae is confined to VT serotypes, vaccine use also reduces antibiotic resistance. With development of PCV, there was a great advance in the prevention of pneumococcal diseases, but replacement with potential virulent organisms and development of antibiotic resistance in non-VT pneumococci is a possibility that needs careful monitoring.